Trial Profile

A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary) ; Sugemalimab (Primary)
Indications Gastric cancer; Solid tumours
Focus Adverse reactions; Proof of concept
Sponsors CStone Pharmaceuticals

Most Recent Events

05 May 2022 Status changed from recruiting to completed.
23 Sep 2020 Planned number of patients changed from 138 to 150.
24 Jan 2020 Status changed from not yet recruiting to recruiting, according to an CStone Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com